New drug cocktail targets genetic weakness in rare cancer

NCT ID NCT05774899

Recruiting now Disease control Sponsor: Glenn J. Hanna Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study tests two different oral drug combinations in people with a rare type of salivary gland cancer called adenoid cystic carcinoma (ACC) that has a specific genetic change (NOTCH mutation). The goal is to see if combining a NOTCH-blocking drug (CB-103) with either abemaciclib or lenvatinib can slow tumor growth and improve survival. The trial enrolls adults with advanced or recurrent ACC that cannot be cured by surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CB-103, abemaciclib, lenvatinib
What this could lead to: If successful, this could provide a new treatment option for people with a rare, hard-to-treat cancer that has a specific genetic mutation.
What could go wrong: This is an early-phase trial with a small number of participants, so the combinations may not prove effective or may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoid cystic carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOID CYSTIC CARCINOMA METASTATIC ADENOID CYSTIC CARCINOMA RECURRENT ADENOID CYSTIC CARCINOMA

Contacts and locations

Locations

Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.